Platinum(IV) Prodrugs – A Step Closer to Ehrlich's Vision?

143Citations
Citations of this article
101Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The concept of the “magic bullet”, a medicine designed to hit a specific biological target, was pioneered by Paul Ehrlich, the father of chemotherapy, some 100 years ago. Building on Ehrlich's vision, we have endeavoured to showcase not only how targeted PtIV prodrugs may be exploited to reduce systemic toxicities associated with modern-day chemotherapeutics, including classical PtII drugs, but also how these prodrugs may overcome resistance issues that have plagued many chemotherapeutic regimes. A summary of advances in this field over the past decade is provided, with an emphasis on PtIV prodrugs that target not only DNA but also enzymes, proteins, peptides and hormones. Synthetic strategies for accessing PtIV chemistry are also provided.

Cite

CITATION STYLE

APA

Kenny, R. G., Chuah, S. W., Crawford, A., & Marmion, C. J. (2017, March 27). Platinum(IV) Prodrugs – A Step Closer to Ehrlich’s Vision? European Journal of Inorganic Chemistry. Wiley-VCH Verlag. https://doi.org/10.1002/ejic.201601278

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free